Systems modeling of metabolic dysregulation in neurodegenerative diseases.

Autor: Baloni P; Institute for Systems Biology, Seattle, WA, USA., Funk CC; Institute for Systems Biology, Seattle, WA, USA., Readhead B; Onegevity, a Division of Thorne HealthTech, New York, NY, USA; Arizona State University-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, USA., Price ND; Institute for Systems Biology, Seattle, WA, USA; Onegevity, a Division of Thorne HealthTech, New York, NY, USA. Electronic address: nathan.price@isbscience.org.
Jazyk: angličtina
Zdroj: Current opinion in pharmacology [Curr Opin Pharmacol] 2021 Oct; Vol. 60, pp. 59-65. Date of Electronic Publication: 2021 Aug 02.
DOI: 10.1016/j.coph.2021.06.012
Abstrakt: Neurodegenerative diseases (NDDs) encompass a wide range of conditions that arise owing to progressive degeneration and the ultimate loss of nerve cells in the brain and peripheral nervous system. NDDs such as Alzheimer's, Parkinson's, and Huntington's diseases negatively impact both length and quality of life, due to lack of effective disease-modifying treatments. Herein, we review the use of genome-scale metabolic models, network-based approaches, and integration with multiomics data to identify key biological processes that characterize NDDs. We describe powerful systems biology approaches for modeling NDD pathophysiology by leveraging in silico models that are informed by patient-derived multiomics data. These approaches can enable mechanistic insights into NDD-specific metabolic dysregulations that can be leveraged to identify potential metabolic markers of disease and predisease states.
Competing Interests: Conflict of interest statement Nothing declared.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: